B. Riley FBR Maintains Buy on Spectrum Pharmaceuticals, Lowers Price Target to $11

B. Riley FBR analyst Mayank Mamtani maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $18 to $11.

Benzinga · 12/27/2019 13:32

B. Riley FBR analyst Mayank Mamtani maintains Spectrum Pharmaceuticals (NASDAQ:SPPI) with a Buy and lowers the price target from $18 to $11.